Matches in SemOpenAlex for { <https://semopenalex.org/work/W2051209842> ?p ?o ?g. }
- W2051209842 endingPage "220" @default.
- W2051209842 startingPage "215" @default.
- W2051209842 abstract "To determine the activity and pharmacodynamics (PD) of bortezomib in platinum-sensitive epithelial ovarian or primary peritoneal cancer (EOC/PPC).Eligible women with recurrent EOC/PPC progressing between 6 and 12 months after initial chemotherapy were treated with bortezomib on days 1, 4, 8, and 11 [1.5 (cohort I) and 1.3 (cohort II) mg/m(2)/dose]. Patients must have had initial chemotherapy only. Response Evaluation Criteria in Solid Tumors (RECIST) was assessed by computed tomography (CT) scan every 2 cycles. 20S proteasome activity was quantified in three pre-treatment and a 1-hour post-treatment (cycle one, day 1) whole blood lysates.Initially, 26 evaluable patients were treated at the 1.5 mg/m(2)/dose level. Objective response rate was 3.8% (1/26), a partial response. An additional 10 patients (38.5%) had stable disease. Given concerns that treatment discontinuations due to toxicity limited drug exposure/activity a second cohort of 29 evaluable patients was accrued at 1.3 mg/m(2)/dose. The 1.3 mg/m(2)/dose regimen is currently approved as an indication for multiple myeloma and mantle cell lymphoma. Treatment was more tolerable, although objective responses remained low at 6.9% (2/29, partial responses). Second stage accrual was not warranted at either dose. Bortezomib effectively inhibited 20S proteasome activity in whole blood lysates between 37 and 92% in 24/25 (96%) patients in cohort I, and 14-84% in 27/28 (96%) patients in cohort II who provided satisfactory pre- and post-treatment specimens for testing.Bortezomib has minimal activity as a single-agent in the treatment of recurrent platinum-sensitive EOC/PPC. Treatment with bortezomib at 1.5 mg/m(2)/dose was not feasible in this patient population due to excess toxicity. Bortezomib was well tolerated at 1.3 mg/m(2)/dose." @default.
- W2051209842 created "2016-06-24" @default.
- W2051209842 creator A5008367436 @default.
- W2051209842 creator A5012218355 @default.
- W2051209842 creator A5016917647 @default.
- W2051209842 creator A5043175553 @default.
- W2051209842 creator A5050845228 @default.
- W2051209842 creator A5054602117 @default.
- W2051209842 creator A5061736280 @default.
- W2051209842 creator A5071052216 @default.
- W2051209842 creator A5085457452 @default.
- W2051209842 creator A5088971630 @default.
- W2051209842 date "2009-11-01" @default.
- W2051209842 modified "2023-09-27" @default.
- W2051209842 title "A phase II evaluation of bortezomib in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: A Gynecologic Oncology Group study" @default.
- W2051209842 cites W1492606093 @default.
- W2051209842 cites W1837700344 @default.
- W2051209842 cites W1888783223 @default.
- W2051209842 cites W1935443268 @default.
- W2051209842 cites W1960327677 @default.
- W2051209842 cites W1968557197 @default.
- W2051209842 cites W1983202503 @default.
- W2051209842 cites W1984458529 @default.
- W2051209842 cites W1985275612 @default.
- W2051209842 cites W2009296843 @default.
- W2051209842 cites W2021413266 @default.
- W2051209842 cites W2024846074 @default.
- W2051209842 cites W2026043555 @default.
- W2051209842 cites W2040809334 @default.
- W2051209842 cites W2043103956 @default.
- W2051209842 cites W2067530043 @default.
- W2051209842 cites W2082575834 @default.
- W2051209842 cites W2083615074 @default.
- W2051209842 cites W2101759139 @default.
- W2051209842 cites W2110159294 @default.
- W2051209842 cites W2127358965 @default.
- W2051209842 cites W2127760782 @default.
- W2051209842 cites W2131915887 @default.
- W2051209842 cites W2143589401 @default.
- W2051209842 cites W2152065071 @default.
- W2051209842 cites W2152091753 @default.
- W2051209842 cites W2158470148 @default.
- W2051209842 cites W2164710551 @default.
- W2051209842 cites W2166043738 @default.
- W2051209842 cites W2166350458 @default.
- W2051209842 cites W2324088026 @default.
- W2051209842 doi "https://doi.org/10.1016/j.ygyno.2009.07.023" @default.
- W2051209842 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19712963" @default.
- W2051209842 hasPublicationYear "2009" @default.
- W2051209842 type Work @default.
- W2051209842 sameAs 2051209842 @default.
- W2051209842 citedByCount "49" @default.
- W2051209842 countsByYear W20512098422012 @default.
- W2051209842 countsByYear W20512098422013 @default.
- W2051209842 countsByYear W20512098422014 @default.
- W2051209842 countsByYear W20512098422015 @default.
- W2051209842 countsByYear W20512098422016 @default.
- W2051209842 countsByYear W20512098422017 @default.
- W2051209842 countsByYear W20512098422018 @default.
- W2051209842 countsByYear W20512098422020 @default.
- W2051209842 countsByYear W20512098422021 @default.
- W2051209842 countsByYear W20512098422022 @default.
- W2051209842 crossrefType "journal-article" @default.
- W2051209842 hasAuthorship W2051209842A5008367436 @default.
- W2051209842 hasAuthorship W2051209842A5012218355 @default.
- W2051209842 hasAuthorship W2051209842A5016917647 @default.
- W2051209842 hasAuthorship W2051209842A5043175553 @default.
- W2051209842 hasAuthorship W2051209842A5050845228 @default.
- W2051209842 hasAuthorship W2051209842A5054602117 @default.
- W2051209842 hasAuthorship W2051209842A5061736280 @default.
- W2051209842 hasAuthorship W2051209842A5071052216 @default.
- W2051209842 hasAuthorship W2051209842A5085457452 @default.
- W2051209842 hasAuthorship W2051209842A5088971630 @default.
- W2051209842 hasConcept C111113717 @default.
- W2051209842 hasConcept C112705442 @default.
- W2051209842 hasConcept C121608353 @default.
- W2051209842 hasConcept C126322002 @default.
- W2051209842 hasConcept C126894567 @default.
- W2051209842 hasConcept C141071460 @default.
- W2051209842 hasConcept C143998085 @default.
- W2051209842 hasConcept C2776364478 @default.
- W2051209842 hasConcept C2776694085 @default.
- W2051209842 hasConcept C2777478702 @default.
- W2051209842 hasConcept C2778367456 @default.
- W2051209842 hasConcept C2778822529 @default.
- W2051209842 hasConcept C2779984678 @default.
- W2051209842 hasConcept C2780427987 @default.
- W2051209842 hasConcept C2780435969 @default.
- W2051209842 hasConcept C2781413609 @default.
- W2051209842 hasConcept C71924100 @default.
- W2051209842 hasConcept C72563966 @default.
- W2051209842 hasConcept C90924648 @default.
- W2051209842 hasConceptScore W2051209842C111113717 @default.
- W2051209842 hasConceptScore W2051209842C112705442 @default.
- W2051209842 hasConceptScore W2051209842C121608353 @default.
- W2051209842 hasConceptScore W2051209842C126322002 @default.
- W2051209842 hasConceptScore W2051209842C126894567 @default.
- W2051209842 hasConceptScore W2051209842C141071460 @default.